{"url_path":"/sec/cmpx/8-k/2026-06-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1738021/0001171843-26-004068-index.html","accession_number":"0001171843-26-004068","cik":"0001738021","ticker":"CMPX","issuer_name":"Compass Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1738021/0001171843-26-004068-index.html","primary_entity_key":"0001738021","primary_entity_name":"Compass Therapeutics, Inc."},"word_count":305,"has_tables":true,"body_markdown":"false\n0001738021\n\n0001738021\n\n2026-06-10\n2026-06-10\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n** **\n\n****\n\n \n\n** **\n\n****\n\n**FORM 8-K**\n\n** **\n\n****\n\n \n\n** **\n\n**CURRENT REPORT**\n\n \n\n**Pursuant to Section 13 or 15(d)**\n\n**of the Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported): June 10, 2026**\n\n** **\n\n****\n\n \n\n** **\n\n**COMPASS THERAPEUTICS, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n \n\n \n\n**Delaware**\n**001-39696**\n**82-4876496**\n\n(State or Other Jurisdiction of Incorporation)\n(Commission File Number)\n(I.R.S. Employer Identification No.)\n\n \n\n**80 Guest Street, Suite 601**\n\n**Boston, Massachusetts 02135**\n\n(Address of Principal Executive Offices) (Zip Code)\n\n \n\n**(617) 500-8099**\n\n(Registrant's telephone number, including area code)\n\n \n\n(Former name or former address, if changed since last report)\n\n \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy\nthe filing obligation of the registrant under any of the following provisions:\n\n \n\n☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\nTrading Symbol(s)\nName of each exchange on which registered\n\nCommon Stock, $0.0001 par value per share\nCMPX\nNASDAQ Capital Market\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined\nin Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2\nof this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not\nto use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section\n13(a) of the Exchange Act. ☐"}